查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2081924

感染疾病診斷市場：2026-2032年全球市場預測（依產品、檢體類型、檢測類型、病原體類型、疾病類型和最終用戶分類）

Infectious Disease Diagnostic Market by Product, Sample Type, Testing Type, Pathogen Type, Disease Type, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，感染疾病診斷市場將成長至 492.8 億美元，複合年成長率為 8.93%。

主要市場統計數據
基準年 2025 270.6億美元
預計年份：2026年 294.1億美元
預測年份：2032年 492.8億美元
複合年成長率 (%) 8.93%

感染疾病診斷市場執行摘要

感染疾病診斷是臨床實踐和公共衛生的基礎，它能夠實現傳染病的檢測、確診、監測和控制。該市場涵蓋分子診斷、免疫檢測、快速抗原檢測、微生物培養檢測、抗菌藥物敏感性試驗、定序、症候群檢測和就地檢驗技術，廣泛應用於醫院、實驗室、公共衛生機構和分散式醫療機構。

感染疾病診斷的變革性變化

感染疾病診斷格局正從集中式的單一病原體檢測轉向分散式模式，從而實現更快速、多參數的同步檢測。雖然PCR和其他核酸增幅檢查對於高靈敏度檢測仍然至關重要，但快速抗原檢測、側向層析檢測和患者端分子診斷平台正在擴大檢測的可及性，尤其是在檢測結果報告時間直接影響隔離、治療、抗生素選擇和疫情控制的情況下。

人工智慧的累積影響

人工智慧（AI）並非僅僅取代實驗室科學，而是正成為感染疾病診斷整體的基礎。 AI驅動的影像分析可以輔助數位顯微鏡檢查、細菌檢測和放射影像的分類。此外，機器學習模型與檢驗的臨床和流行病學數據相結合，可以幫助評估敗血症風險、最佳化抗生素使用、標記異常檢測結果，甚至預測疫情爆發。

感染疾病診斷的區域趨勢

亞太地區感染疾病，加之中國、印度、日本、韓國、澳洲和東協等國分子檢測能力的不斷提升，因此該地區是感染疾病診斷的重中之重。世界衛生組織一直將東南亞和西太平洋地區定位為結核病和蟲媒病毒感染疾病監測的中心區域，並強調了快速診斷檢測、分子檢測和加強公共衛生檢查室建設的持續需求。

戰略集團對傳染病檢查的見解

東協地區的需求主要受登革熱季節性、結核病防治、呼吸道感染疾病、跨境人口流動以及島嶼、農村和高密度都市區醫療衛生系統對可擴展的照護現場診斷的需求等因素驅動。該地區的公共衛生重點在於推動潛在流行性疾病的快速抗原檢測、分子診斷確診檢測、檢查室間聯網以及數位化報告。

來自各國對診斷需求影響的見解

美國在分子診斷、公共衛生報告、檢查室自建檢測能力以及FDA監管下的創新方面處於主導，而加拿大則專注於省際檢查室聯網、抗生素抗藥性監測和呼吸道病毒監測。墨西哥和巴西對登革熱、結核病、愛滋病、肝炎和呼吸道病原體等傳染病檢查需求旺盛，其中巴西也受益於其完善的公共衛生機構、豐富的監測經驗和本地生產能力。

為行業領導者提供的實用建議

產業領導者應優先考慮檢驗的高通量分子診斷平台、快速照護現場檢測、抗生素敏感性檢測工具以及針對呼吸道感染疾病、性行為感染感染、敗血症、結核病、愛滋病、肝炎、瘧疾、登革熱和抗生素抗藥性的多重檢測組合。產品策略必須與臨床工作流程、報銷理由、檢體到結果的便利性、品管、互聯互通性和總體擁有成本一致。

調查方法

本調查方法是基於已驗證的二手研究，並對公共衛生、監管和科學領域的檢驗，資料來源包括世界衛生組織（WHO）、美國疾病管制與預防中心（CDC）、歐洲疾病預防控制中心（ECDC）、美國食品藥物管理局（FDA）、聯合國愛滋病規劃署（UNAIDS）、各國衛生機構、同行評審文獻以及主要感染疾病監測報告。研究評估了疾病負擔、監管方向、診斷流程、技術檢驗模式和公共衛生優先事項，並確定了推動產業永續發展的促進因素。

結論

感染疾病診斷正邁入一個以速度、分散化、基因組智慧、抗生素抗藥性監測和網路化監測為特徵的新時代。由於結核病、瘧疾、愛滋病、呼吸道病毒、患者照護、肝炎、醫療相關感染和抗藥性病原體等疾病的全球負擔仍然存在，因此，準確的檢測對於個別患者的治療和公共衛生安全仍然至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：感染疾病診斷市場：依產品分類

  • 裝置
    • 免疫檢測裝置
    • 質譜儀
    • 微陣列
    • PCR系統
  • 試劑和試劑盒
    • 抗原檢測試劑盒
    • ELISA試劑盒
    • 免疫檢測盒
    • PCR試劑盒
  • 軟體

第8章：感染疾病診斷市場：依檢體類型分類

  • 血
  • 航班
  • 拭子
    • 鼻腔
    • 直腸
    • 咽
  • 尿

第9章：感染疾病診斷市場：依檢測類型分類

  • 臨床試驗
  • PoC測試

第10章：感染疾病診斷市場：依病原體類型分類

  • 細菌
  • 真菌
  • 寄生蟲
  • 病毒性的
    • 肝炎
    • HIV
    • 流感

第11章：感染疾病診斷市場：依疾病類型分類

  • 細菌性行為感染
    • 腦膜炎
    • 肺炎
    • 結核
  • 黴菌感染疾病
    • 麴菌症
    • 念珠菌症
    • 隱球菌病
  • 寄生蟲感染疾病
    • 利什曼原蟲症
    • 瘧疾
    • 血吸蟲病
  • 媒介性行為感染感染
    • 登革熱
    • 萊姆病
    • 茲卡病毒
  • 性行為感染
    • 肝炎（甲型、乙型、丙型）
    • 乙型肝炎及丙型肝炎
    • 愛滋病毒/愛滋病
    • 流感

第12章：感染疾病診斷市場：依最終用戶分類

  • 學術研究機構
  • 診斷實驗室
  • 醫院和診所

第13章：感染疾病診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章：感染疾病診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：感染疾病診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Adaptive BIoTechnologies Corporation
  • Agilent Technologies, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bio-Techne Corporation
  • bioMerieux SA
  • Boston Scientific Corporation
  • Bruker Corporation
  • Cardinal Health Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Grifols, SA
  • Hologic Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services Inc.
  • Konica Minolta, Inc.
  • Koninklijke Philips NV
  • MedMira Inc.
  • Medtronic PLC
  • Merck KGaA
  • Olympus Corporation
  • Perkin Elmer, Inc.
  • Pfizer Inc.
  • Qiagen NV
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
  • Trivitron Healthcare
Product Code: MRR-4316E4E89510

The Infectious Disease Diagnostic Market is projected to grow by USD 49.28 billion at a CAGR of 8.93% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 27.06 billion
Estimated Year [2026] USD 29.41 billion
Forecast Year [2032] USD 49.28 billion
CAGR (%) 8.93%

Infectious Disease Diagnostics Executive Summary

Infectious disease diagnostics form the clinical and public health backbone for detecting, confirming, monitoring, and controlling communicable diseases. The market spans molecular diagnostics, immunoassays, rapid antigen tests, culture-based microbiology, antimicrobial susceptibility testing, sequencing, syndromic panels, and point-of-care testing used across hospitals, reference laboratories, public health agencies, and decentralized care settings.

Demand remains anchored in measurable disease burden. WHO reported 10.8 million tuberculosis cases in 2023 and an estimated 263 million malaria cases in 2023; UNAIDS reported nearly 40 million people living with HIV in 2024; and antimicrobial resistance was associated with 1.27 million attributable deaths in 2019. These realities continue to prioritize accurate, fast, and scalable infectious disease testing that supports timely treatment, outbreak containment, and evidence-based surveillance.

Transformative Shifts in Infectious Disease Diagnostics

The infectious disease diagnostic landscape is shifting from centralized, single-pathogen testing toward faster, multiplexed, and decentralized models. PCR and other nucleic acid amplification tests remain essential for high-sensitivity detection, while rapid antigen, lateral flow, and near-patient molecular platforms are expanding access where turnaround time directly affects isolation, treatment, antimicrobial selection, and outbreak control.

Public health surveillance is also becoming more integrated with clinical diagnostics. Wastewater monitoring, genomic sequencing, antimicrobial susceptibility testing, and electronic laboratory reporting are increasingly linked to preparedness programs. At the same time, IVDR implementation in Europe, FDA oversight in the United States, and quality requirements for laboratory-developed tests are raising expectations for analytical validation, traceability, clinical evidence, and post-market performance.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming an enabling layer across infectious disease diagnostics rather than a standalone replacement for laboratory science. AI-supported image analysis can assist digital microscopy, colony recognition, and radiology triage, while machine learning models can prioritize sepsis risk, optimize antimicrobial stewardship, flag abnormal laboratory patterns, and support outbreak forecasting when connected to validated clinical and epidemiological data.

The cumulative impact is faster decision support, improved laboratory workflow, and stronger population-level surveillance. However, adoption depends on transparent validation, representative datasets, cybersecurity, interoperability, bias monitoring, and clinician oversight. Industry leaders that combine AI with regulatory-grade evidence, laboratory information systems, and explainable outputs will be better positioned to convert automation into trusted diagnostic value.

Regional Dynamics Across Infectious Disease Diagnostics

Asia-Pacific is a high-priority infectious disease diagnostics region due to large population scale, persistent TB, dengue, hepatitis, malaria, and respiratory infection burden, and expanding molecular testing capacity in China, India, Japan, South Korea, Australia, and ASEAN countries. WHO has consistently identified South-East Asia and the Western Pacific as central regions for tuberculosis and arboviral disease surveillance, supporting continued demand for rapid diagnostic tests, molecular assays, and public health laboratory strengthening.

North America remains a technology leader, supported by CLIA-certified laboratories, FDA-cleared diagnostic platforms, CDC surveillance networks, strong laboratory quality systems, and rapid uptake of syndromic and molecular testing for respiratory pathogens, sexually transmitted infections, sepsis, and healthcare-associated infections. Latin America faces recurring dengue, Zika, chikungunya, TB, HIV, and respiratory disease pressures, driving demand for affordable rapid tests, decentralized sample collection, and regional reference laboratory capacity.

Europe is shaped by strong public health systems, antimicrobial resistance programs, cross-border disease surveillance, and EU IVDR compliance, with laboratories prioritizing validated assays, traceability, and quality management. The Middle East is investing in laboratory modernization and preparedness linked to international travel, migration, and mass-gathering risks, while Africa remains central to global diagnostic access priorities for HIV, TB, malaria, cholera, viral hemorrhagic fevers, and outbreak-prone pathogens.

Strategic Group Insights for Infectious Disease Testing

ASEAN demand is influenced by dengue seasonality, TB control, respiratory infections, cross-border mobility, and the need for scalable point-of-care diagnostics across island, rural, and high-density urban health systems. The region's public health priorities support rapid antigen testing, molecular confirmation, laboratory networking, and digital reporting for diseases with epidemic potential.

GCC countries are advancing laboratory automation, molecular diagnostics, and biosurveillance through hospital investment, public health modernization, and preparedness for travel-associated infections and mass-gathering events. The European Union is defined by harmonized regulatory expectations under IVDR, ECDC-led surveillance coordination, antimicrobial resistance strategies, and laboratory quality requirements that favor clinically validated and traceable diagnostic solutions.

BRICS countries combine high infectious disease burden with expanding diagnostic infrastructure, domestic manufacturing capacity, and public health programs focused on TB, HIV, hepatitis, malaria, respiratory infections, and antimicrobial resistance. G7 markets lead in R&D funding, reimbursement depth, pandemic preparedness, genomic surveillance, and advanced laboratory automation, while NATO members increasingly view infectious disease diagnostics as part of biosecurity, resilience, and civilian-military health preparedness.

Country-Level Insights Shaping Diagnostic Demand

The United States leads in molecular diagnostics adoption, public health reporting, laboratory-developed testing capacity, and FDA-regulated innovation, while Canada emphasizes coordinated provincial laboratory networks, antimicrobial resistance monitoring, and respiratory virus surveillance. Mexico and Brazil show strong demand for affordable infectious disease testing across dengue, TB, HIV, hepatitis, and respiratory pathogens, with Brazil also benefiting from established public health institutes, surveillance experience, and local production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are shaped by public reimbursement, hospital laboratory consolidation, antimicrobial resistance programs, respiratory surveillance, and IVDR transition planning, while Russia maintains demand across TB, viral hepatitis, HIV, and respiratory testing. These countries continue to prioritize diagnostic quality, laboratory automation, and validated molecular and immunoassay platforms aligned with national health systems.

China and India represent large-scale diagnostic priorities due to population size, domestic manufacturing, expanding hospital networks, and significant infectious disease burden, including TB, viral hepatitis, dengue, respiratory infections, and antimicrobial resistance concerns. Japan, Australia, and South Korea are advanced diagnostic markets with strong quality systems, aging populations, high uptake of automated molecular and syndromic testing, and active surveillance for influenza, COVID-19, antimicrobial resistance, and emerging pathogens.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize validated, high-throughput molecular platforms, rapid point-of-care formats, antimicrobial susceptibility tools, and multiplex panels that address respiratory infections, sexually transmitted infections, sepsis, TB, HIV, hepatitis, malaria, dengue, and antimicrobial resistance. Product strategies should align with clinical workflows, reimbursement evidence, sample-to-answer usability, quality control, connectivity, and total cost of ownership.

Organizations should also invest in regional manufacturing resilience, regulatory readiness, and data connectivity. Partnerships with public health agencies, hospitals, non-governmental organizations, and reference laboratories can accelerate adoption in underserved regions. AI capabilities should be embedded only where they improve accuracy, turnaround time, workflow efficiency, antimicrobial stewardship, or surveillance value and are supported by auditable clinical evidence.

Research Methodology

The research methodology is built from verified secondary research and data triangulation across public health, regulatory, and scientific sources, including WHO, CDC, ECDC, FDA, UNAIDS, national health agencies, peer-reviewed literature, and major infectious disease surveillance reports. Disease burden, regulatory direction, diagnostic workflow, technology adoption patterns, and public health priorities were assessed to identify durable industry drivers.

The methodology emphasizes evidence-based interpretation rather than speculative forecasting. Insights were validated through cross-source comparison, with attention to disease prevalence, diagnostic performance, laboratory infrastructure, regulatory controls, regional healthcare capacity, procurement dynamics, and surveillance needs. Conclusions were framed to support strategic planning for diagnostic manufacturers, laboratories, healthcare providers, investors, public health organizations, and policymakers.

Conclusion

Infectious disease diagnostics are moving into a new era defined by speed, decentralization, genomic intelligence, antimicrobial resistance monitoring, and connected surveillance. Persistent global burdens from TB, malaria, HIV, respiratory viruses, dengue, hepatitis, healthcare-associated infections, and drug-resistant pathogens ensure that accurate testing remains essential to both individual care and public health security.

The strongest industry positions will belong to organizations that combine scientific validity, regulatory compliance, scalable access, workflow integration, and digital connectivity. As healthcare systems prepare for endemic threats and future outbreaks, diagnostics will continue to serve as the first line of detection, the guide for targeted treatment, and the foundation for evidence-based infectious disease control.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Infectious Disease Diagnostic Market, by Product

  • 7.1. Instruments
    • 7.1.1. Immunoassay Analyzers
    • 7.1.2. Mass Spectrometers
    • 7.1.3. Microarrays
    • 7.1.4. PCR Systems
  • 7.2. Reagents & Kits
    • 7.2.1. Antigen Detection Kits
    • 7.2.2. ELISA Kits
    • 7.2.3. Immunoassay Kits
    • 7.2.4. PCR Kits
  • 7.3. Software

8. Infectious Disease Diagnostic Market, by Sample Type

  • 8.1. Blood
  • 8.2. Stool
  • 8.3. Swab
    • 8.3.1. Nasal
    • 8.3.2. Rectal
    • 8.3.3. Throat
  • 8.4. Urine

9. Infectious Disease Diagnostic Market, by Testing Type

  • 9.1. Laboratory Testing
  • 9.2. PoC Testing

10. Infectious Disease Diagnostic Market, by Pathogen Type

  • 10.1. Bacterial
  • 10.2. Fungal
  • 10.3. Parasitic
  • 10.4. Viral
    • 10.4.1. Hepatitis
    • 10.4.2. HIV
    • 10.4.3. Influenza

11. Infectious Disease Diagnostic Market, by Disease Type

  • 11.1. Bacterial Infectious Diseases
    • 11.1.1. Meningitis
    • 11.1.2. Pneumonia
    • 11.1.3. Tuberculosis
  • 11.2. Fungal Infections
    • 11.2.1. Aspergillosis
    • 11.2.2. Candidiasis
    • 11.2.3. Cryptococcosis
  • 11.3. Parasitic Infections
    • 11.3.1. Leishmaniasis
    • 11.3.2. Malaria
    • 11.3.3. Schistosomiasis
  • 11.4. Vector-borne Infections
    • 11.4.1. Dengue Fever
    • 11.4.2. Lyme Disease
    • 11.4.3. Zika Virus
  • 11.5. Viral Infectious Diseases
    • 11.5.1. Hepatitis (A, B, C)
    • 11.5.2. Hepatitis B & C
    • 11.5.3. HIV/AIDS
    • 11.5.4. Influenza

12. Infectious Disease Diagnostic Market, by End-User

  • 12.1. Academic & Research Institutes
  • 12.2. Diagnostic Laboratories
  • 12.3. Hospitals & Clinics

13. Infectious Disease Diagnostic Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Infectious Disease Diagnostic Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Infectious Disease Diagnostic Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Adaptive Biotechnologies Corporation
  • 17.3. Agilent Technologies, Inc.
  • 17.4. Becton, Dickinson and Company
  • 17.5. Bio-Rad Laboratories, Inc.
  • 17.6. Bio-Techne Corporation
  • 17.7. bioMerieux SA
  • 17.8. Boston Scientific Corporation
  • 17.9. Bruker Corporation
  • 17.10. Cardinal Health Inc.
  • 17.11. Danaher Corporation
  • 17.12. F. Hoffmann-La Roche Ltd.
  • 17.13. GE HealthCare Technologies Inc.
  • 17.14. Grifols, S.A.
  • 17.15. Hologic Inc.
  • 17.16. Illumina, Inc.
  • 17.17. Johnson & Johnson Services Inc.
  • 17.18. Konica Minolta, Inc.
  • 17.19. Koninklijke Philips N.V.
  • 17.20. MedMira Inc.
  • 17.21. Medtronic PLC
  • 17.22. Merck KGaA
  • 17.23. Olympus Corporation
  • 17.24. Perkin Elmer, Inc.
  • 17.25. Pfizer Inc.
  • 17.26. Qiagen N.V.
  • 17.27. Quest Diagnostics Incorporated
  • 17.28. Siemens Healthineers AG
  • 17.29. Sysmex Corporation
  • 17.30. Thermo Fisher Scientific, Inc.
  • 17.31. Trivitron Healthcare

LIST OF FIGURES

  • FIGURE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNOASSAY ANALYZERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MASS SPECTROMETERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MICROARRAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROARRAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICROARRAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PCR SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PCR SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PCR SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIGEN DETECTION KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ELISA KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ELISA KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ELISA KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNOASSAY KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PCR KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PCR KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PCR KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SOFTWARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL SOFTWARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SOFTWARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL STOOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL STOOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RECTAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL THROAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THROAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THROAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LABORATORY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL LABORATORY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL LABORATORY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POC TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POC TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POC TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL FUNGAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL FUNGAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL FUNGAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARASITIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARASITIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARASITIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HEPATITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HEPATITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HEPATITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HIV MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BACTERIAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MENINGITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MENINGITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MENINGITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL PNEUMONIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL PNEUMONIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL PNEUMONIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TUBERCULOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TUBERCULOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL FUNGAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL ASPERGILLOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL ASPERGILLOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL ASPERGILLOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL CANDIDIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANDIDIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL CANDIDIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL CRYPTOCOCCOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL LEISHMANIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL LEISHMANIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL LEISHMANIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL MALARIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL MALARIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL MALARIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL SCHISTOSOMIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL VECTOR-BORNE INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL DENGUE FEVER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL DENGUE FEVER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL DENGUE FEVER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL LYME DISEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL LYME DISEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL LYME DISEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL ZIKA VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL ZIKA VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL ZIKA VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL VIRAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HEPATITIS (A, B, C) MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HEPATITIS B & C MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HEPATITIS B & C MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HEPATITIS B & C MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV/AIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HIV/AIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV/AIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL ACADEMIC & RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 258. GLOBAL INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 275. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 277. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 278. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 279. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 281. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 284. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 287. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 288. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 289. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 290. GCC INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 291. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 293. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 294. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 295. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 307. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 309. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 310. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 311. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 313. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 323. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 325. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 327. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 328. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 329. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 331. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 332. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 334. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 335. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 336. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VECTOR-BORNE INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 337. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 338. G7 INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 339. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 340. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 341. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 342. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 343. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 345. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY TESTING TYPE, 2018-2032 (USD MILLION)
  • TABLE 346. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PATHOGEN TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY VIRAL, 2018-2032 (USD MILLION)
  • TABLE 348. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 349. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY BACTERIAL INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 350. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY FUNGAL INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 351. NATO INFECTIOUS DISEASE DIAGNOSTIC MARKET SIZE, BY PARASITIC INFECTIONS, 2018-2032 (USD MILLION)
  • TABLE 352. NATO INFECTIO